X linked Charcot-Marie-Tooth disease and multiple sclerosis: emerging evidence for an association

Objective X linked Charcot-Marie-Tooth disease (CMTX) is a hereditary neuropathy caused by mutations in GJB1 coding for connexin-32, a gap junction protein expressed in Schwann cells, but also found in oligodendrocytes. Four patients with CMTX developing central nervous system (CNS) demyelination compatible with multiple sclerosis (MS) have been individually published. We presently sought to systematically investigate the relationship between CMTX and MS. Methods Over 20 years, 70 consecutive patients (36 men) with GJB1 mutations were identified at our Neurogenetics Unit, Athens, Greece, and assessed for clinical features suggestive of MS. Additionally, 18 patients with CMTX without CNS symptoms and 18 matched controls underwent brain MRI to investigate incidental findings. Serum from patients with CMTX and MS was tested for CNS immunoreactivity. Results We identified three patients with CMTX who developed clinical features suggestive of inflammatory CNS demyelination fulfilling MS diagnostic criteria. The resulting 20-year MS incidence (4.3%) differed significantly from the highest background 20-year MS incidence ever reported from Greece (p=0.00039). The search for incidental brain MRI findings identified two CMTX cases (11%) with lesions suggestive of focal demyelination compared with 0 control. Moreover, 10 cases in the CMTX cohort had hyperintensity in the splenium of the corpus callosum compared with 0 control (p=0.0002). No specific CNS-reactive humoral factors were identified in patients with CMTX and MS. Conclusions We have demonstrated a higher than expected frequency of MS in patients with CMTX and identified incidental focal demyelinating lesions on brain MRI in patients with CMTX without CNS symptoms. This provides circumstantial evidence for GJB1 mutations acting as a possible MS risk factor.

[1]  S. Erimaki,et al.  Whole exome sequencing establishes diagnosis of Charcot–Marie–Tooth 4J, 1C, and X1 subtypes , 2020, Molecular genetics & genomic medicine.

[2]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[3]  R. Lewis,et al.  Cross-sectional analysis of a large cohort with X-linked Charcot-Marie-Tooth disease (CMTX1) , 2017, Neurology.

[4]  H. Houlden,et al.  Mutations in noncoding regions of GJB1 are a major cause of X-linked CMT , 2017, Neurology.

[5]  Sarah Wong,et al.  Loss of Coupling Distinguishes GJB1 Mutations Associated with CNS Manifestations of CMT1X from Those Without CNS Manifestations , 2017, Scientific Reports.

[6]  Chang-hyun Park,et al.  Cerebral white matter abnormalities in patients with charcot‐marie‐tooth disease , 2017, Annals of neurology.

[7]  M. Muglia,et al.  A rare association between multiple sclerosis and Charcot‐Marie‐Tooth type 1B , 2016, Brain and behavior.

[8]  I. Sargiannidou,et al.  Systemic inflammation disrupts oligodendrocyte gap junctions and induces ER stress in a model of CNS manifestations of X-linked Charcot-Marie-Tooth disease , 2016, Acta neuropathologica communications.

[9]  F. Yin,et al.  A Review of X-linked Charcot-Marie-Tooth Disease , 2016, Journal of child neurology.

[10]  M. Reindl,et al.  Antibody biomarkers in CNS demyelinating diseases – a long and winding road , 2015, European journal of neurology.

[11]  G. Koutsis,et al.  Relapsing Remitting Multiple Sclerosis in X-Linked Charcot-Marie-Tooth Disease with Central Nervous System Involvement , 2015, Case reports in neurological medicine.

[12]  K. Fujihara,et al.  MOG cell-based assay detects non-MS patients with inflammatory neurologic disease , 2015, Neurology: Neuroimmunology & Neuroinflammation.

[13]  I. Sargiannidou,et al.  A start codon CMT1X mutation associated with transient encephalomyelitis causes complete loss of Cx32 , 2015, neurogenetics.

[14]  M. Dalakas,et al.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders , 2015, Nature Reviews Neurology.

[15]  G. Koutsis,et al.  Four novel connexin 32 mutations in X-linked Charcot–Marie–Tooth disease. Phenotypic variability and central nervous system involvement , 2014, Journal of the Neurological Sciences.

[16]  F. Baas,et al.  PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and Hereditary Neuropathy with liability to Pressure Palsies , 2014, Orphanet Journal of Rare Diseases.

[17]  M. Ramanathan,et al.  Prevalence of Radiologically Isolated Syndrome and White Matter Signal Abnormalities in Healthy Relatives of Patients with Multiple Sclerosis , 2014, American Journal of Neuroradiology.

[18]  E. Andreadou,et al.  Central Nervous System Demyelination in a Charcot-Marie-Tooth Type 1A Patient , 2013, Case reports in neurological medicine.

[19]  J. Polke,et al.  Clinical implications of genetic advances in Charcot–Marie–Tooth disease , 2013, Nature Reviews Neurology.

[20]  A. Kochański,et al.  Charcot-Marie-Tooth type 1C disease coexisting with progressive multiple sclerosis: a study of an overlapping syndrome. , 2012, Folia neuropathologica.

[21]  P. Vermersch,et al.  Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[22]  B. Engelhardt,et al.  T‐cell trafficking in the central nervous system , 2012, Immunological reviews.

[23]  R. Reynolds,et al.  Disruption of oligodendrocyte gap junctions in experimental autoimmune encephalomyelitis , 2012, Glia.

[24]  R. Reynolds,et al.  Gap junction pathology in multiple sclerosis lesions and normal-appearing white matter , 2012, Acta Neuropathologica.

[25]  Satoshi O. Suzuki,et al.  Extensive loss of connexins in Baló’s disease: evidence for an auto-antibody-independent astrocytopathy via impaired astrocyte–oligodendrocyte/myelin interaction , 2012, Acta Neuropathologica.

[26]  M. Bähr,et al.  Inflammatory demyelinating CNS disorder in a case of X-linked Charcot–Marie–Tooth disease: positive response to natalizumab , 2012, Journal of Neurology.

[27]  J. Cunningham,et al.  Large kindred evaluation of mitofusin 2 novel mutation, extremes of neurologic presentations, and preserved nerve mitochondria. , 2011, Archives of neurology.

[28]  M. Shroff,et al.  MRI findings in X-linked Charcot-Marie-Tooth disease associated with a novel connexin 32 mutation. , 2011, Clinical radiology.

[29]  D. Goodin,et al.  Incidental MRI anomalies suggestive of multiple sclerosis , 2009, Neurology.

[30]  M. Panas,et al.  Central motor and sensory pathway involvement in an X-linked Charcot-Marie-Tooth family. , 2008, Acta neurologica Belgica.

[31]  L. Messinis,et al.  Prevalence and Incidence of Multiple Sclerosis in Western Greece: A 23-Year Survey , 2008, Neuroepidemiology.

[32]  Y. Parman,et al.  X-linked Charcot-Marie-Tooth disease and multiple sclerosis , 2007, Journal of Neurology.

[33]  M. Panas,et al.  Four novel connexin 32 mutations in X–linked Charcot–Marie–Tooth disease with phenotypic variability , 2006, Journal of Neurology.

[34]  R. Abbott,et al.  Charcot‐Marie‐Tooth disease due to the Thr124Met mutation in the myelin protein zero gene associated with multiple sclerosis , 2005, Journal of the peripheral nervous system : JPNS.

[35]  M. Nobile,et al.  X-linked Charcot-Marie-Tooth disease and progressive-relapsing central demyelinating disease , 2005, Neurology.

[36]  P. Calabresi,et al.  Anti-&agr;4 integrin therapy for multiple sclerosis: Mechanisms and rationale , 2005, Neurology.

[37]  K. Zerres,et al.  Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation. , 2003, Archives of neurology.

[38]  M. Zwarts,et al.  Transient cerebral white matter lesions in a patient with connexin 32 missense mutation , 2002, Neurology.

[39]  K. Fischbeck,et al.  Transient central nervous system white matter abnormality in X‐linked Charcot‐Marie‐Tooth disease , 2002, Annals of neurology.

[40]  S. Scherer,et al.  Cellular mechanisms of connexin32 mutations associated with CNS manifestations , 2002, Journal of neuroscience research.

[41]  M. Panas,et al.  Episodes of generalized weakness in two sibs with the C164T mutation of the connexin 32 gene , 2001, Neurology.

[42]  J. Dichgans,et al.  Central visual, acoustic, and motor pathway involvement in a Charcot-Marie-Tooth family with an Asn205Ser mutation in the connexin 32 gene , 1999, Journal of neurology, neurosurgery, and psychiatry.

[43]  D. Avramopoulos,et al.  Central nervous system involvement in four patients with Charcot-Marie-Tooth disease with connexin 32 extracellular mutations , 1998, Journal of neurology, neurosurgery, and psychiatry.

[44]  W. Seltzer,et al.  Demyelinating neuropathy in a patient with multiple sclerosis and genotypical HMSN-1 , 1998, Neuromuscular Disorders.

[45]  G. Moretto,et al.  Multiple sclerosis associated with duplicated CMT1A: a report of two cases , 1997, Journal of neurology, neurosurgery, and psychiatry.

[46]  T. Olsson,et al.  Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis , 2017, Nature Reviews Neurology.

[47]  S. Scherer,et al.  Molecular genetics of X-linked Charcot-Marie-Tooth disease , 2007, NeuroMolecular Medicine.

[48]  H. Sasaki,et al.  X-linked Charcot-Marie-Tooth disease (CMTX) in a severely affected female patient with scattered lesions in cerebral white matter. , 2007, Internal medicine.

[49]  D. Sharp,et al.  Coexistent hereditary and inflammatory neuropathy. , 2004, Brain : a journal of neurology.

[50]  W. L. Benedict,et al.  Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.